Fibromyalgia is a difficult disease to treat due to patient heterogeneity, frequent comorbid conditions, and a variety of symptoms including pain, depression, fatigue, and sleep dysfunction. The few drugs that are formally approved for the treatment of fibromyalgia (Pfizer’s Lyrica, Pierre Fabre’s/Allergan’s Savella, duloxetine) have limited efficacy, resulting in off-label use of a variety of antidepressants, analgesics, muscle relaxants, and sleep aids to manage patient symptoms. Although the recognition, diagnosis, and treatment of fibromyalgia has improved dramatically over the past decade, the treatment journeys of fibromyalgia patients are highly complex, with high rates of treatment discontinuation, drug-switching, and polypharmacy.
Treatment Algorithms: Claims Data Analysis provides detailed analysis of brand usage across different lines of therapy using real-world, patient-level claims data, so you can accurately assess your source of business and quantify areas of opportunity for increasing your brand share.
Markets covered: United States
Real-world data: Longitudinal patient-level claims data analysis
Key companies: Pfizer, Allergan, Pierre-Fabre
Key drugs: Lyrica, Savella, duloxetine, gabapentin, SNRIs, SSRIs, muscle relaxants, NSAIDs, opioid analgesics, sedative hypnotics, and others
Key analysis provided: